Table 3.

Multivariate Analysis of Outcome Predictors in 98 Patients With Multiple Myeloma Who Developed Neutropenia-Related Aspergillosis

Variable	Odds Ratio	95% Confidence Interval	P
Response based on s-GMI kinetics
Baseline
Platelet count (per 1000 platelets/mm3)	1.009	1.001–1.017	.03
After diagnosis of aspergillosis
Neutrophil recoverya	32.734	3.630–295.164	.002
s-GMI normalization ≤7 days from diagnosis of IA	5.356	1.316–21.901	.02
Response based on the EORTC/MSG definitions
Baseline
Platelet count (per 1000 platelets/mm3)	1.009	1.002–1.017	.01
Creatinine clearance rate (per mL/min)	1.024	1.006–1.042	.009
After diagnosis of aspergillosis
s-GMI normalization ≤7 days from diagnosis of IA	2.900	1.009–8.333	.048
Response based on 6-week survival
Baseline
Creatinine clearance rate (per mL/min)	1.031	1.010–1.052	.003
After diagnosis of aspergillosis			NS

Outcomes were examined according to the kinetics of serum Aspergillus galactomannan, the EORTC/MSG response definitions, and 6-week survival. Variables were defined at baseline and after the diagnosis of aspergillosis.

Abbreviations: IA, invasive aspergillosis; EORTC/MSG, European Organization for Research and Treatment of Cancer/Mycosis Study Group; NS, not significant; s-GMI, serum Aspergillus galactomannan index.

^a Defined as an ANC of ≥500 neutrophils/mm³ on 3 consecutive days.